📰 Cassava Sciences News
Page 22 - Cassava Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cassava Sciences. Real-time updates on events, politics, business and more.
March 14, 2023
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
February 27, 2023
/PRNewswire/ -- The prevalence of Alzheimers disease has been rising over the past few years, which prompts the growing demand for treatment options. The...
February 9, 2023
/PRNewswire/ -- The "Alzheimers Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028" report has been added to ResearchAndMarkets....
February 8, 2023
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete...
February 1, 2023
It isn't about running out of money, but it's still laden with risk.
January 31, 2023
Cybersecurity company allegedly engages in ‘channel stuffing’ to inflate sales figures
January 26, 2023
Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly. See the outlook here.
January 25, 2023
Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimers disease dementia. This was an open-label safety study with exploratory... | January 25, 2023
January 20, 2023
/PRNewswire/ -- The "Alzheimers Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of...
January 11, 2023
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.